Skip to content
TrialScanner

NCT02909452

Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1CompletedSNDXLeadMRKCollaborator

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Bronchial Neoplasms; Lung Neoplasms
Primary completion
Jul 17, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02909452 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02909452: Continuation Study of... | TrialScanner